# AblaView > AblaView is developing the first polarization-sensitive optical coherence reflectometry (PS-OCR) platform for real-time guidance of cardiac ablation procedures. The system provides tissue characterization, contact assessment, lesion prediction, and safety detection during atrial fibrillation ablation. First-in-human study published in Europace (February 2025) demonstrated 100% specificity for durable pulsed-field ablation lesion prediction at three-month follow-up. ## What AblaView is AblaView is a medical device company. Its core product is a fiber-optic cardiac ablation catheter paired with a console and a Clinical AI Engine. The system uses PS-OCR to see inside cardiac tissue during ablation and reports in real time on contact quality, lesion depth, lesion durability, and proximity to critical structures (vessels, nerves, conduction system). The technology supports both radiofrequency (RF) and pulsed-field ablation (PFA) energy modalities, and the optical guidance layer is energy-agnostic so it can be integrated with third-party RF and PFA ablation platforms. ## Key pages - [Homepage](https://ablaview.com/): The recurrence problem in atrial fibrillation ablation, the PS-OCR mechanism (direct birefringence measurement, 50 micron axial resolution), the peer-reviewed evidence with named investigators, the three-minute corporate film, and the moat: 70+ patents plus 860+ histology-paired preclinical ablations - [Technology](https://ablaview.com/technology): PS-OCR optical sensing, the four-model Clinical AI Engine (M1 Tissue Classification and Gap Detection, M2 Contact Assessment, M3 Lesion Prediction, M4 Safety Detection), hardware platform, sub-50ms latency on NVIDIA IGX Orin - [Clinical Data](https://ablaview.com/clinical): First-in-human results published in Europace 2025;27(2):euaf009. NCT06700226. 100% specificity for durable PFA lesion prediction at three-month follow-up. No hemolysis, no neurovascular complications. - [Pipeline](https://ablaview.com/pipeline): Programme status for the Clinical AI Engine, PS-OCR dual-energy catheter, and OEM guidance layer. FDA pre-submission programme active. Dated milestones are shared with qualified partners under NDA. - [Publications](https://ablaview.com/publications): Peer-reviewed journal articles only (Europace 2025 first-in-human, Circulation 2024 preclinical). Conference materials are shared with qualified partners on request. Request route for the full evidence package. - [Team](https://ablaview.com/team): Board of directors, executive team, and a medical advisory board of thirteen advisors across seven countries, including McGill, Imperial College London, Sunnybrook, and CHU Rennes - [Careers](https://ablaview.com/careers): Open roles in Madrid (hardware engineer, production technician, biomedical engineer), why the work matters, and how the hiring process runs. Applications go by email. - [Investors](https://ablaview.com/investors): The thesis in four lines (100% specificity in Europace February 2025, EUR 68M+ absorbed, 70+ patents and 25 TB of data, Series A in progress) plus a register-your-interest form. Round size, terms, and dated milestones are shared with qualified investors under NDA. - [Press Kit](https://ablaview.com/press): Approved boilerplate, brand assets, executive bios, single media contact - [Privacy Policy](https://ablaview.com/privacy), [Cookie Policy](https://ablaview.com/cookies), [Terms of Use](https://ablaview.com/terms), [Legal Notice](https://ablaview.com/legal), [Accessibility Statement](https://ablaview.com/accessibility) ## Heritage and assets The AblaView catheter programme was built within MedLumics S.L. in Madrid (company founded 2009; catheter programme initiated three years later, after early OCT and dermatology work). More than 68 million euros of equity and non-dilutive funding underpinned the twelve-year catheter programme. In 2026 AblaView S.L. acquired the full technology, 70+ active patents across 9 jurisdictions, 25 terabytes of proprietary preclinical and clinical PS-OCR data paired with histology, manufacturing capability, and the technical team outright, with zero legacy obligations. The acquisition is backed by Innogate Enterprises. Round-level investor detail is shared with qualified investors under NDA. ## Regulatory status Investigational device. The AblaView system is under preclinical and clinical investigation. It is not FDA approved nor CE labelled. The current working assumption is an FDA 510(k) pathway with predicate analysis under way, supported by a Predetermined Change Control Plan drafted against FDA 2024 final guidance for AI/ML-enabled medical device software, and an active FDA pre-submission programme. Specific submission and clearance dates depend on regulator feedback and are shared with qualified investors under NDA. ## Clinical evidence summary The first-in-human study enrolled ten patients undergoing PVI ablation for atrial fibrillation using a unipolar PFA catheter with integrated PS-OCR guidance. The primary reported result was intraprocedural lesion-durability prediction measured against the three-month electroanatomic remap. Result: 100% specificity for predicting durable lesions confirmed at follow-up remap. No device-related serious adverse events, no hemolysis, no neurovascular complications. Lead author Dr. Maria Terricabras (Sunnybrook, University of Toronto). Co-authors and proctors during the first-in-human cases: Prof. Atul Verma (McGill University Health Centre) and Prof. Raphael Martins (CHU Rennes). A preclinical PS-OCR validation study was published in Circulation, 2024. ## Market Cardiac electrophysiology is the fastest-growing category in interventional cardiology, with approximately 1.4 million ablation procedures performed globally each year and an estimated 7 to 9 percent annual growth rate. More than one in five patients require a repeat ablation within twelve months. AblaView addresses this redo-rate problem by confirming durable lesion formation during the procedure rather than at a three-month remap. ## Business model Three revenue streams: capital equipment placement (console per EP lab), recurring single-use fiber-optic catheters per procedure, and OEM licensing of the guidance layer to existing ablation catheter manufacturers post-clearance. ## Contact - General: info@ablaview.com - Investors: investors@ablaview.com - Clinical and research: clinical@ablaview.com - Privacy and data: privacy@ablaview.com - Security disclosures: see https://ablaview.com/.well-known/security.txt ## Disclaimer All material on ablaview.com is for qualified healthcare professionals, investors, and research partners only. It is not medical advice. The AblaView PS-OCR system is investigational and is not intended to diagnose, treat, cure, or prevent any disease outside the scope of an approved clinical investigation.